Haemovigilance: Giving it our best SHOT!

Erica M Wood^{1

2}, Barbee I Whitaker³, Mary Townsend⁴

Affiliations

¹ School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
² Department of Clinical Haematology, Monash Health, Melbourne, Australia.
³ Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
⁴ Vitalant, Scottsdale, Arizona, USA.

Erica M Wood et al. Vox Sang. 2023 Apr.

. 2023 Apr;118(4):260-262.

doi: 10.1111/vox.13411. Epub 2023 Feb 20.

Erica M Wood^{1

2}, Barbee I Whitaker³, Mary Townsend⁴

¹ School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
² Department of Clinical Haematology, Monash Health, Melbourne, Australia.
³ Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
⁴ Vitalant, Scottsdale, Arizona, USA.

No abstract available

References

1. Narayan S, editor Poles D on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. et al. The 2021 Annual SHOT Report. 2022.
1. International Society of Blood Transfusion [cited 16 Jan 2023]. Available from: https://www.isbtweb.org/resources/hv-tools.html.
1. De Jonge LL, Wiersum-Osselton JC, Bokhorst AG, Schipperus MR, Zwaginga JJ. Haemovigilance: current practices and future developments. Ann Blood. 2022;7:23.
1. Wood EM, Ang AL, Bisht A, Bolton-Maggs P, Bokhorst A, Flesland O, et al. International haemovigilance: what have we learned and what do we need to do next? Transfus Med. 2019;29:221-30.
1. Burns KE, Haysom HE, Higgins AM, Waters N, Tahiri R, Rushford K, et al. A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major. Transfus Med. 2019;29:33-40.